Liege, Belgium, 24 April 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has entered into a capital commitment agreement with LDA Capital Limited, a Los Angeles based global investment group with expertise in cross border transactions in life science sector.
Liege, Belgium, 22 April 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces the publication of its 2019 Annual Report and the invitation to its Ordinary and Extraordinary General Securities holders.
2019 Annual Report
The Annual Report which outlines Mithra’s achievements in 2019 includes the following information:
- Overview of Mithra’s R&D pipeline and Letter to Shareholders;
- Highlights of Mithra’s Strategy and Outlook for 2020;
- Management Report;
- Remuneration Report;
- Financial statements and notes.
The Annual Report is available in English and French and can be read (or downloaded in PDF) on the website investors.mithra.com. In case of interpretation differences, the French version will prevail.
François Fornieri, CEO Mithra Women’s Health, commented:
“2019 marked our 20th anniversary and was exceptional in more ways than one. We recorded a strong turnover increase, achieved key milestones in both clinical development and international growth, and a CDMO that successfully moved into commercial production. In 2020, despite this unprecedented situation caused by Covid-19, our teams are determined to do everything possible to meet our ambitious challenges.”
General Shareholders’ meeting
Mithra is pleased to invite its securities holders to its Ordinary and Extraordinary General Shareholder’s meeting that will be held on Friday May 22 2020 at 2:00 PM (CEST).
The notice for the General Shareholder’s Meeting including a description of the formalities to participate in the Meeting is available on the website investors.mithra.com.
Exceptional organisational arrangements due to Covid-19 have been made
16 April 2020, Adelaide Australia and Liege, Belgium – Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) today announced that Mayne Pharma has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA), seeking marketing authorisation for E4/DRSP, a combined oral contraceptive indicated for the prevention of pregnancy in women. If approved by the FDA, E4/DRSP is expected to be made available to patients in the US market in the first half of calendar 2021.
- Successful launch of Mithra’s hormonal contraceptive ring in Germany under the trademark MYCIRQ®
- Germany is the largest European market and the second worldwide, with 3 million vaginal rings sold per year
- Mithra CDMO pursues the manufacturing of its Myring™ orders in compliance with all the measures required by the Belgian authorities
Liege, Belgium, 2 April 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces the commercial launch of Myring™ in Germany, which is the largest European market and the second worldwide in terms of sales volume. With 3 million vaginal rings sold per year, the German contraceptive rings market is worth EUR 27 million per year.
Liege, Belgium, 01 April 2020 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces an update on the Donesta® Phase III Clinical Program called “E4 Comfort”, which aims at enrolling approximately 2200 menopausal women (40-65 years) and includes two pivotal studies: in North America (United States/Canada) launched in October 2019, and in Europe, Russia and South America launched in December 2019. For each pivotal study, women will be recruited in about 120 sites in the concerned areas.
Rue Saint-Georges 5
Tel. : +32 (0)4 349 28 22
Fax : +32 (0)4 349 28 21
Email : email@example.com